<SEC-DOCUMENT>0000200406-18-000052.txt : 20181023
<SEC-HEADER>0000200406-18-000052.hdr.sgml : 20181023
<ACCEPTANCE-DATETIME>20181023164847
ACCESSION NUMBER:		0000200406-18-000052
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181023
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181023
DATE AS OF CHANGE:		20181023

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		181134552

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a201810238-kciz.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB6EBB69F8B7350CDDBF99CB9241D77D1"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURRENT REPORT</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:144%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Exchange Act of 1934</font></div><div style="line-height:144%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):&#160;&#160;October 23, 2018</font></div><div style="line-height:144%;text-align:center;"><img src="jnjlogoa06.jpg" alt="jnjlogoa06.jpg" style="height:45px;width:180px;"></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:35%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:144%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;08933</font></div><div style="line-height:144%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:144%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;&#160;732-524-0400</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company    </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Events.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 23, 2018, Johnson &amp; Johnson ("J&amp;J") announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the &#8220;Company&#8221;), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all-cash offer (the &#8220;tender offer&#8221;) to acquire all of the outstanding shares of the Company not already held by J&amp;J and its affiliates for &#165;5,900 per share, which equates to approximately &#165;230 billion (approximately $2 billion, using the exchange rate of 112.82 Japanese Yen to each U.S. Dollar&#160;as of 5 p.m., New York City time, on October 22, 2018).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition will include the Company&#8217;s range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skincare products.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, Cilag GmbH International, an affiliate of J&amp;J (&#8220;Cilag&#8221;), entered into a long-term strategic collaboration with the Company, to distribute the Company&#8217;s brands outside of Japan. As part of this collaboration, Cilag acquired approximately 19.9% of the outstanding shares of the Company. The tender offer is part of a series of transactions pursuant to which J&amp;J intends to acquire all the outstanding shares of the Company, including a separate transaction whereby J&amp;J will acquire the shares of the Company held by CIC Corporation, the ownership vehicle of the Company&#8217;s founder, Dr. Yoshinori Shirono. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J&amp;J expects to launch the tender offer on October 29, 2018.&#160; Additional information on the tender offer and transactions will be made available to the Company&#8217;s shareholders in the tender offer registration statement for the transaction to be filed on EDINET in Japan.  Copies of an English translation of the tender offer explanatory statement, which includes all the information described in the tender offer registration statement, may be obtained by contacting J&amp;J&#8217;s tender offer agent, SMBC Nikko (IBG_M&amp;A_JPN@smbcnikko-si.com) at any time after October 29, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tender offer is expected to close in the first quarter of 2019. Upon completion of the tender offer, J&amp;J intends to conduct a squeeze-out procedure to purchase the remaining shares in the Company that were not tendered in the tender offer, which we expect to complete in the first half of 2019.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proposed transaction is conditioned upon:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J&amp;J&#8217;s having acquired, directly or indirectly, at least two-thirds of all Company shares that are issued and outstanding at the end of the tender offer period, which may be extended, including for this purpose: the shares tendered, the shares already held by Cilag, and the shares held by CIC Corporation that will be separately acquired by J&amp;J;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further customary offer conditions described in the tender offer registration statement, including regulatory approvals.</font></div></td></tr></table><div style="line-height:144%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related press release dated October 23, 2018 is attached as Exhibit 99.1 to this report.</font></div><div style="line-height:144%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:144%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:25%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a201810238-kcizex991.htm"><font style="font-family:inherit;font-size:10pt;">99.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson Press Release dated October 23, 2018.</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:144%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:7%;"></td><td style="width:33%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant)</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;&#160;October 23, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Renee A. Brutus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renee A. Brutus</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assistant Corporate Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a201810238-kcizex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF1568D2B4ED9308C53049CE92AC374D2"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;padding-bottom:16px;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div><div style="line-height:144%;padding-bottom:12px;text-align:center;"><img src="jnjlogoa06.jpg" alt="jnjlogoa06.jpg" style="height:49px;width:192px;"></div><div style="line-height:209%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media Contacts:</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ernie Knewitz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Donna Lorenson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-6623</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(410) 258-8571</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(917) 697-2318 (M)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">dlorens@its.jnj.com  </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">eknewitz@its.jnj.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mel Tyndale-Biscoe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+65 8798 2475 (Singapore)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Contact:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Lisa Romanko</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition is Expected to Expand J&amp;J&#8217;s Consumer Portfolio of </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Science-based Dermocosmetic Beauty Products</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NEW BRUNSWICK, NJ, October 23, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- Johnson &amp; Johnson (NYSE: JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the &#8220;Company&#8221;), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all-cash offer (the &#8220;tender offer&#8221;) to acquire all of the outstanding shares of the Company not already held by Johnson &amp; Johnson and its affiliates for &#165;5,900 per share, which equates to approximately &#165;230 billion. The acquisition will include the Company&#8217;s range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skincare products.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s skincare portfolio is expected to strengthen Johnson &amp; Johnson&#8217;s market presence in Japan with key customers, and more broadly bolster its offering in science-based, efficacious dermocosmetic brands. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Health and beauty consumers are actively seeking science-based innovation to improve their skin,&#8221; said Jorge Mesquita, Worldwide Chairman, Johnson &amp; Johnson Consumer. &#8220;This transaction will maximise value creation for Johnson &amp; Johnson&#8217;s Consumer business by bringing in an agile innovation model and rapidly accelerating sales through our global commercialization expertise.&#8221;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, Cilag GmbH International, an affiliate of Johnson &amp; Johnson (&#8220;Cilag&#8221;), entered into a long-term strategic collaboration with the Company, to distribute the Company&#8217;s brands outside of Japan. As part of this collaboration, Cilag acquired approximately 19.9% of the outstanding shares of the Company. The tender offer is part of a series of transactions pursuant to which Johnson &amp; Johnson intends to acquire all the outstanding shares of the Company, including a separate transaction whereby Johnson &amp; Johnson will acquire the shares of the Company held by CIC Corporation, the ownership vehicle of the Company&#8217;s founder, Dr. Yoshinori Shirono. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Benefits of the Proposed Transaction</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:-1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Compelling, all-cash transaction for the Company&#8217;s shareholders:</font><font style="font-family:inherit;font-size:10pt;">&#32;The transaction will deliver a significant and immediate premium to the Company&#8217;s shareholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:-1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-enhancing transaction for Johnson &amp; Johnson shareholders:</font><font style="font-family:inherit;font-size:10pt;">&#32;The transaction would enhance long-term growth and value creation of the Johnson &amp; Johnson Consumer business;</font></div></td></tr></table><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:-1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Elevating connected commerce capabilities</font><font style="font-family:inherit;font-size:10pt;">: The transaction will be a springboard to build Johnson &amp; Johnson Consumer&#8217;s connected commerce capabilities by leveraging one of the largest customer relationship management databases for direct-to-consumer skincare in Japan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:-1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expanding and improving distribution through well-established networks: </font><font style="font-family:inherit;font-size:10pt;">The addition of the Company to the Johnson &amp; Johnson Family of Companies will provide the opportunity to expand and improve retail presence through Johnson &amp; Johnson&#8217;s Consumer capabilities and well-established distribution networks; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:-1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strengthening international innovation pipeline: </font><font style="font-family:inherit;font-size:10pt;">The transaction will provide a strong platform for portfolio expansion by leveraging Johnson &amp; Johnson&#8217;s global innovation pipeline.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Roadmap to Completion</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson expects to launch the tender offer on October 29, 2018.&#160; Additional information on the tender offer and transactions will be made available to the Company&#8217;s shareholders in the tender offer registration statement for the transaction to be filed on EDINET in Japan.  Copies of an English translation of the tender offer explanatory statement, which includes all the information described in the tender offer registration statement, may be obtained by contacting Johnson &amp; Johnson&#8217;s tender offer agent, SMBC Nikko (</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">IBG_M&amp;A_JPN@smbcnikko-si.com</font><font style="font-family:inherit;font-size:10pt;">) at any time after October 29, 2018.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tender offer is expected to close in the first quarter of 2019. Upon completion of the tender offer, Johnson &amp; Johnson intends to conduct a squeeze-out procedure to purchase the remaining shares in the Company that were not tendered in the tender offer, which we expect to complete in the first half of 2019.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proposed transaction is conditioned upon:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:-1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson&#8217;s having acquired, directly or indirectly, at least two-thirds of all Company shares that are issued and outstanding at the end of the tender offer period, which may be extended, including for this purpose: the shares tendered, the shares already held by Cilag, and the shares held by CIC Corporation that will be separately acquired by Johnson &amp; Johnson;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:-1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further customary offer conditions described in the tender offer registration statement, including regulatory approvals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Johnson &amp; Johnson </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At Johnson &amp; Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IMPORTANT ADDITIONAL INFORMATION&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The public tender offer described herein has not yet commenced. This press release is for informational purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares of the Company, nor shall it form the basis of, or be relied on in connection with, any contract there for. At the time the tender offer is commenced, shareholders of&#160;the Company&#160;are urged to read the tender offer documents when they become available. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE CONCERNING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential transaction between&#160;Johnson &amp; Johnson&#160;and&#160;the Company. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of&#160;Johnson &amp; Johnson&#160;and&#160;the Company. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the transaction, including the receipt of regulatory approvals for the transaction; the tender of the requisite amount of the outstanding shares of the Company; the possibility that the transaction will not be completed in the expected timeframe or at all; the potential that the expected benefits and opportunities of the transaction, if completed, may not be realized or may take longer to realize than expected; uncertainty of commercial success for new and existing products; manufacturing difficulties and delays; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, </font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">new products and patents attained by competitors; changes to applicable laws and regulations, including tax laws and domestic and foreign health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of the&#160;Johnson &amp; Johnson&#160;Family of Companies to successfully integrate the products, employees and operations of&#160;the Company, as well as the ability to ensure continued performance or market growth of&#160;the Company&#8217;s products. A further list and description of these risks, uncertainties and other factors can be found in&#160;Johnson &amp; Johnson's&#160;publicly available filings with the&#160;U.S. Securities and Exchange Commission. Copies of these filings, as well as subsequent filings, are available online at&#160;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">,&#160;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.jnj.com</font><font style="font-family:inherit;font-size:10pt;">&#32;or on request from&#160;Johnson &amp; Johnson. Johnson &amp; Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media Contacts:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ernie Knewitz&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-6623 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(917) 697-2318 (M)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">eknewitz@its.jnj.com</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mel Tyndale-Biscoe</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+65 8798 2475 (Singapore)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Donna Lorenson</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(410) 258-8571</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">dlorens@its.jnj.com</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Contact:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lisa Romanko</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-2034 </font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>jnjlogoa06.jpg
<TEXT>
begin 644 jnjlogoa06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  24DJ  @    $ !H!!0 !
M    /@   !L!!0 !    1@   "@! P !     @!$<C$! @ 0    3@
M  !@     0   &     !    4&%I;G0N3D54('8T+C P /_; $,  @$! 0$!
M @$! 0(" @("! ," @("!00$ P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&" L,"PH,"0H*"O_; $,! @(" @("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_  !$( "\
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MM-M(Y-R->3[<[Y4>*),95V<*GO\ \ +OQGJ/P3\(ZA\1]7_M'Q%/X:L)=8U
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M;)'ZU^9?_!6#]GV[MI/BU9? 37HK/3?$7@6/Q7\8M&DM/,BCGL)U?3[F!O\
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M>]S<THTXT^;X5RIJ-^7WO>E+WM;*; ]*,#TH'2BNK0^?"C ]*** "C ]***
.."C SG%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
